Anticancer agent 231

Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC50 value of 3.95 μM. Anticancer agent 231 inhibits the cell viability, cell proliferation, cell migration and cancer dryness of triple negative breast cancer (TNBC) cells by targeting EGFR-ERK 1/2 signaling pathway, and is expected to play an important role in the field of TNBC disease therapy[1].

Product Specifications

CAS Number

[128519-30-2]

UNSPSC

12352005

Target

ERK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Stem Cell/Wnt

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/anticancer-agent-231.html

Smiles

ClC1=CC=C(C2=NN(C3=CC=CC=C3)C(C4=CC=C(N(C)C)C=C4)C2)C=C1

Molecular Formula

C23H22ClN3

Molecular Weight

375.89

References & Citations

[1]Satriyo PB, et al. N-phenyl pyrazoline derivative inhibits cell aggressiveness and enhances paclitaxel sensitivity of triple negative breast cancer cells. Sci Rep. 2024 Jun 8;14 (1) :13200.